Spots Global Cancer Trial Database for Nicotine Skin Patch in Treating Patients With Kaposi's Sarcoma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Nicotine Skin Patch in Treating Patients With Kaposi's Sarcoma

Official Title: Treatment of Classical Kaposi Sarcoma With Nicotine Dermal Patch: A Phase II Trial

Study ID: NCT00295984

Conditions

Sarcoma

Interventions

nicotine

Study Description

Brief Summary: RATIONALE: Nicotine may stimulate the immune system to kill Kaposi's sarcoma cells. PURPOSE: This phase II trial is studying the side effects and how well the nicotine skin patch works in treating patients with Kaposi's sarcoma.

Detailed Description: OBJECTIVES: * Evaluate the toxicity and efficacy of transdermal nicotine applied to lesions in patients with classic Kaposi's Sarcoma. OUTLINE: This is a double-blind, placebo-controlled study. Patients apply a nicotine dermal patch to a selected lesion and a placebo patch to the other lesion, replacing the same type of fresh patch every other day, during the first 2 weeks, increasing the nicotine dose in week 3 and again in week 5 for a total of 15 weeks in the absence of disease progression or unacceptable toxicity. PROJECTED ACCRUAL: A total of 24 patients will be accrued for this study.